Related Experiment Video

Updated: Feb 3, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

The therapeutic role of ivabradine in heart failure

Charles Badu-Boateng1, Robert Jennings1, Daniel Hammersley2

  • 1Department of Medicine, Frimley Park Hospital, Frimley, Camberley, UK.

Therapeutic Advances in Chronic Disease
|October 27, 2018
PubMed

Insights

Ivabradine, a heart rate-lowering drug, is approved for specific heart failure patients. This review details its mechanism, clinical trials, and use in managing heart failure with reduced ejection fraction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure is a significant global health burden, causing widespread morbidity and mortality.
  • Current treatments for heart failure with reduced ejection fraction (HFrEF) aim to improve outcomes but may not sufficiently control heart rate.
  • Sustained elevated heart rate in HFrEF is associated with adverse prognosis.

Purpose of the Study:

  • To review the mechanism of action of ivabradine, a selective funny current (If) inhibitor.
  • To evaluate the clinical evidence supporting the use of ivabradine in heart failure management.
  • To discuss the current clinical recommendations for ivabradine in patients with symptomatic HFrEF and elevated heart rate.

Main Methods:

  • Literature review of preclinical studies and clinical trials on ivabradine in heart failure.
  • Analysis of data from pivotal trials investigating ivabradine's efficacy and safety.
  • Synthesis of current guidelines and expert opinions on ivabradine's role in HFrEF.

Main Results:

  • Ivabradine selectively inhibits the sinoatrial node If current, reducing heart rate without affecting other cardiac parameters.
  • Clinical trials demonstrate that ivabradine, when added to optimal therapy, reduces heart rate and improves cardiovascular outcomes in selected HFrEF patients.
  • Benefits are observed in patients with symptomatic HFrEF and a resting heart rate ≥70 bpm.

Conclusions:

  • Ivabradine is a valuable therapeutic option for managing symptomatic HFrEF in patients with persistently elevated heart rate.
  • Its mechanism of reducing heart rate offers a complementary approach to standard heart failure pharmacotherapy.
  • Appropriate patient selection based on heart rate and symptoms is crucial for optimizing ivabradine therapy.

Keywords:
drug therapyheart failureivabradine

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319